title: [Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy].
abstract: Interest in simplification arises from the need to dispense with nucleoside analogs due to their long-term toxicity. Since the first trials analyzing the safety and effectiveness of the strategy with lopinavir/ritonavir (LPV/r) emerged more than 10 years ago, simplification continues to arouse scientific, clinical and economic interest. At present, there is no consensus on recommendations; interpretations of results are discordant: while some emphasize the greater risk of loss of virologic control, others indicate that the possible virological rebound with this strategy is unrelated to a loss of therapeutic options or to the emergence of resistance to ritonavir-boosted protease inhibitors. This scenario governs the recommendations that can be made in clinical practice; almost all groups agree that candidates should be selected for a simplification strategy with fewer drugs.
authors.affiliation: Unidad de VIH, Hospital Universitario 12 de Octubre, Madrid, España.
authors.forename: María de Lagarde
authors.initials: Mde L
authors.lastname: Sebastián
authors.affiliation: Unidad de VIH, Hospital Universitario 12 de Octubre, Madrid, España.
authors.forename: Otilia Bisbal
authors.initials: OB
authors.lastname: Pardo
authors.affiliation: Unidad de VIH, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: pulidof@gmail.com.
authors.forename: Federico Pulido
authors.initials: FP
authors.lastname: Ortega
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir / Q000008:administration & dosage / Q000627:therapeutic use*; D055118:Medication Adherence; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D010342:Patient Acceptance of Health Care; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012306:Risk; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D013810:Therapeutic Equivalency; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; C558899:lopinavir-ritonavir drug combination; D061466:Lopinavir; D019438:Ritonavir
keywords: Dual therapy; HIV; Lopinavir/ritonavir; Monoterapia; Monotherapy; Simplificación; Simplification; Terapia dual; VIH